MedTrace Logo

Preliminary Study of Pharmacokinetics of Ginkgolides Meglumine Injection.

NCT02046031 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2014-07-15

No results posted yet for this study

Summary

To explore the rule of absorption, distribution, metabolism and elimination after intravenous administration of Ginkgolides Meglumine Injection healthy subjects. The plasma drug profiles will be important to assess the potential clinical drug-drug interactions.

Conditions

Interventions

DRUG

Ginkgolides Meglumine Injection

25 mg, ivdrip, once.

Sponsors & Collaborators

  • Beijing Bionovo Medicine Development Co., Ltd.

    collaborator OTHER

  • Jiangsu Kanion Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Ou Ning · The First Affiliated Hospital with Nanjing Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02046031 on ClinicalTrials.gov